Literature DB >> 20053750

N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site.

Vasiliy P Mishin1, Makiko Watanabe, Garry Taylor, John Devincenzo, Michael Bose, Allen Portner, Irina V Alymova.   

Abstract

The hemagglutinin-neuraminidase (HN) glycoprotein plays a critical role in parainfluenza virus replication. We recently found that in addition to the catalytic binding site, HN of human parainfluenza virus type 1 (hPIV-1) may have a second receptor-binding site covered by an N-linked glycan at residue 173, which is near the region of the second receptor-binding site identified in Newcastle disease virus (NDV) HN (I. A. Alymova, G. Taylor, V. P. Mishin, M. Watanabe, K. G. Murti, K. Boyd, P. Chand, Y. S. Babu, and A. Portner, J. Virol. 82:8400-8410, 2008). Sequence analysis and superposition of the NDV and hPIV-3 HN dimer structures revealed that, similar to what was seen in hPIV-1, the N-linked glycan at residue 523 on hPIV-3 HN may cover a second receptor-binding site. Removal of this N-linked glycosylation site by an Asn-to-Asp substitution at residue 523 (N523D) changed the spectrum of the mutant virus's receptor specificity, delayed its elution from both turkey and chicken red blood cells, reduced mutant sensitivity (by about half) to the selective HN inhibitor BCX 2855 in hemagglutination inhibition tests, and slowed its growth in LLC-MK(2) cells. The neuraminidase activity of the mutant and its sensitivity to BCX 2855 in neuraminidase inhibition assays did not change, indicating that the mutation did not affect the virus's catalytic-binding site and that all observed effects were caused by the exposure of the purported second receptor-binding site. Our data are consistent with the idea that, similar to the case for hPIV-1, the N-linked glycan shields a second receptor-binding site on hPIV-3 HN.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20053750      PMCID: PMC2826034          DOI: 10.1128/JVI.02331-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Crystallization of Newcastle disease virus hemagglutinin-neuraminidase glycoprotein.

Authors:  T Takimoto; G L Taylor; S J Crennell; R A Scroggs; A Portner
Journal:  Virology       Date:  2000-04-25       Impact factor: 3.616

2.  Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion.

Authors:  Toru Takimoto; Garry L Taylor; Helen C Connaris; Susan J Crennell; Allen Portner
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 3.  The pH of the secretory pathway: measurement, determinants, and regulation.

Authors:  Paul Paroutis; Nicolas Touret; Sergio Grinstein
Journal:  Physiology (Bethesda)       Date:  2004-08

4.  Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host.

Authors:  Catherine I Thompson; Wendy S Barclay; Maria C Zambon
Journal:  J Antimicrob Chemother       Date:  2004-03-17       Impact factor: 5.790

5.  Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice.

Authors:  Makiko Watanabe; Vasiliy P Mishin; Scott A Brown; Charles J Russell; Kelli Boyd; Y Sudhakara Babu; Garry Taylor; Xiaoping Xiong; Xiaowei Yan; Allen Portner; Irina V Alymova
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

6.  Role of matrix and fusion proteins in budding of Sendai virus.

Authors:  T Takimoto; K G Murti; T Bousse; R A Scroggs; A Portner
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Receptor specificities of human respiroviruses.

Authors:  T Suzuki; A Portner; R A Scroggs; M Uchikawa; N Koyama; K Matsuo; Y Suzuki; T Takimoto
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo.

Authors:  Irina V Alymova; Garry Taylor; Toru Takimoto; Tsu-Hsing Lin; Pooran Chand; Y Sudhakara Babu; Chenghong Li; Xiaoping Xiong; Allen Portner
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III.

Authors:  Michael C Lawrence; Natalie A Borg; Victor A Streltsov; Patricia A Pilling; V Chandana Epa; Joseph N Varghese; Jennifer L McKimm-Breschkin; Peter M Colman
Journal:  J Mol Biol       Date:  2004-01-30       Impact factor: 5.469

10.  Second sialic acid binding site in Newcastle disease virus hemagglutinin-neuraminidase: implications for fusion.

Authors:  Viatcheslav Zaitsev; Mark von Itzstein; Darrin Groves; Milton Kiefel; Toru Takimoto; Allen Portner; Garry Taylor
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more
  15 in total

Review 1.  Glycomics and glycoproteomics of viruses: Mass spectrometry applications and insights toward structure-function relationships.

Authors:  John F Cipollo; Lisa M Parsons
Journal:  Mass Spectrom Rev       Date:  2020-04-29       Impact factor: 10.946

2.  The second receptor binding site of the globular head of the Newcastle disease virus hemagglutinin-neuraminidase activates the stalk of multiple paramyxovirus receptor binding proteins to trigger fusion.

Authors:  Matteo Porotto; Zuhair Salah; Ilaria DeVito; Aparna Talekar; Samantha G Palmer; Rui Xu; Ian A Wilson; Anne Moscona
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

3.  Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells In Vitro: Contribution of the Cleavage Site of Fusion Protein and Second Sialic Acid Binding Site of Hemagglutinin-Neuraminidase.

Authors:  Udaya S Rangaswamy; Weijia Wang; Xing Cheng; Patrick McTamney; Danielle Carroll; Hong Jin
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

4.  Inhibition of primary clinical isolates of human parainfluenza virus by DAS181 in cell culture and in a cotton rat model.

Authors:  B G Jones; R T Hayden; J L Hurwitz
Journal:  Antiviral Res       Date:  2013-09-27       Impact factor: 5.970

5.  Receptor-binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein.

Authors:  Irina V Alymova; Allen Portner; Vasiliy P Mishin; Jonathan A McCullers; Pamela Freiden; Garry L Taylor
Journal:  Glycobiology       Date:  2011-08-16       Impact factor: 4.313

Review 6.  Zoonotic Potential of Emerging Paramyxoviruses: Knowns and Unknowns.

Authors:  Patricia A Thibault; Ruth E Watkinson; Andres Moreira-Soto; Jan F Drexler; Benhur Lee
Journal:  Adv Virus Res       Date:  2017-02-02       Impact factor: 9.937

7.  Development of a point-of-care diagnostic for influenza detection with antiviral treatment effectiveness indication.

Authors:  Richard C Murdock; Karen M Gallegos; Joshua A Hagen; Nancy Kelley-Loughnane; Alison A Weiss; Ian Papautsky
Journal:  Lab Chip       Date:  2017-01-17       Impact factor: 6.799

Review 8.  Paramyxovirus entry.

Authors:  Katharine N Bossart; Deborah L Fusco; Christopher C Broder
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 9.  Paramyxovirus fusion and entry: multiple paths to a common end.

Authors:  Andres Chang; Rebecca E Dutch
Journal:  Viruses       Date:  2012-04-19       Impact factor: 5.048

10.  Structure of the ulster strain newcastle disease virus hemagglutinin-neuraminidase reveals auto-inhibitory interactions associated with low virulence.

Authors:  Ping Yuan; Reay G Paterson; George P Leser; Robert A Lamb; Theodore S Jardetzky
Journal:  PLoS Pathog       Date:  2012-08-09       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.